Here are five things to know:
1. With the new expanded coverage, 80 million people now have access to Cologuard through their insurance provider,
2. HCSC’s subsidiaries include Blue Cross and Blue Shield plans in Illinois, Texas, Montana, New Mexico and Oklahoma.
3. Under the updated HCSC policy, Cologuard may be considered medically necessary for colorectal cancer screening for average risk patients, once every three years.
4. Florida Blue’s updated policy notes the “use of an FDA approved fecal DNA test (e.g. Cologuard) meets the definition of medical necessity once every three years as a screening technique for members in whom colorectal cancer preventive screening is indicated (per USPSTF Colorectal Cancer Screening Grade A recommendation).”
5. The FDA approved Cologuard in August 2014.
More articles on GI/endoscopy:
Jeannie Fahlquist joins Benefis Health GI team: 2 thoughts
Valeant, Norgine partner for bowel-cleansing solution; EndoChoice’s Q2 net loss totals $24.7M: 3 GI company key notes
Male PBC patients have higher mortality rates than female: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
